A protocol for a multicentre, randomised, double-blind, placebo-controlled trial to compare the effect of annual infusions of zoledronic acid to placebo on knee structural change and knee pain over 24 months in knee osteoarthritis patients – ZAP2

Abstract Background Bisphosphonates are a class of drugs that slow bone loss and are a promising candidate to treat knee osteoarthritis (OA) patients. In a pilot study, we demonstrated that zoledronic acid reduced knee pain and size of subchondral bone marrow lesions (BMLs) over 6 months in knee OA...

Full description

Bibliographic Details
Main Authors: Dawn Aitken, Laura L. Laslett, Guoqi Cai, Catherine Hill, Lyn March, Anita E. Wluka, Yuanyuan Wang, Leigh Blizzard, Flavia Cicuttini, Graeme Jones
Format: Article
Language:English
Published: BioMed Central 2018-07-01
Series:BMC Musculoskeletal Disorders
Subjects:
Online Access:http://link.springer.com/article/10.1186/s12891-018-2143-2